2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3884 Distinct immunoglobulin recovery trajectories between continuous BTK inhibition and fixed-duration venetoclax-based therapy in treatment-naïve chronic lymphocytic leukemia: A retrospective analysis

Farzeen Syed, DO, Christine Gruessner, MD MPH2, Laura Samples, MD3, Pia Nierman, RN4, Adrian Wiestner, MD, PhD5
1 NHLBI, Bethesda, Maryland, United States, NIH, Bethesda, Maryland, United States
2 NHLBI, Bethesda, Maryland, United States, NIH, Bethesda, Maryland, United States
3 NHLBI, Bethesda, Maryland, United States, NIH, Bethesda, Maryland, United States
4 NHLBI, Bethesda, Maryland, United States, NIH, Bethesda, Maryland, United States
5 NHLBI, Bethesda, Maryland, United States, NIH, Bethesda, Maryland, United States

Background: Immune dysfunction and hypogammaglobulinemia are common in chronic lymphocytic leukemia (CLL), increase infection risk and may require long-term intravenous immunoglobulin (IVIG). Immunoglobulin (Ig) recovery with targeted therapy remains poorly characterized across fixed-duration and continuous regimens. Clonal or incidental paraproteinemia in CLL may confound Ig recovery assessment. We evaluated Ig trajectories in treatment-naïve (TN) CLL patients to assess factors associated with persistent hypogammaglobulinemia and recovery.

Methods: We retrospectively analyzed TN patients from three single-center phase 2 trials: ibrutinib in patients aged ≥65 years or with del(17p) (n=44; NCT01500733), acalabrutinib for del(17p) (n=15; NCT02337829), and venetoclax plus anti-CD20 therapy (Ven; n=22; NCT03986034). Ibrutinib and acalabrutinib formed the continuous Bruton tyrosine kinase inhibitor (BTKi) cohort (n=59). All trials complied with the Declaration of Helsinki. Patients receiving IVIG or other immunomodulatory therapy were excluded.

Baseline paraproteinemia defined M+ and M- cohorts. Patients with incident paraproteinemia remained M-; involved isotypes were censored at detection. IgG, IgA, IgM, and free light chains (FLCs) were normalized to pretreatment baseline and expressed as log2 fold-change in 6-month intervals. Follow-up ended at relapse, progression, or discontinuation, and median trajectories required ≥3 patients per interval. Censoring involved isotypes separated clonal involvement from recovery. Paraproteins were confirmed by immunofixation and flow-cytometric light-chain restriction. BTRIS data were chart-verified and analyzed in R. Recovery was defined as return to the reference range from below normal at baseline. Follow-up was 60 months for BTKi and 36 months for Ven.

Results: Among 81 patients, baseline or incident paraprotein included IgG in 15, IgM in 20, and IgA in 4; some had multiple paraproteins. Baseline paraproteinemia defined the M+ cohort (n=29). In each cohort, M+ patients had higher baseline IgM, consistent with clonal IgM; M+ and M- had similar IGHV status, del(17p), and age. As baseline characteristics differed, cohorts were analyzed separately.

In the BTKi cohort, M+ patients had greater hypogammaglobulinemia extending beyond the involved isotype. Baseline IgG and/or IgA were below normal in 14/22 M+ versus 15/37 M- patients. Among 15 M+ patients with IgM paraprotein, censoring reduced median IgM from 45 to 25 mg/dL; 5/7 evaluable patients remained below normal. On treatment, both M+ and M- patients’ IgA (9/14 vs 9/15) and IgG (4/11 vs 2/12) increased to normal range. By 24 months, clonal IgM decreased while non-clonal IgM increased, indicating loss of tumor-derived IgM rather than impaired recovery.

In the Ven cohort, IgM nadir declined 70% from baseline by treatment end (12 months) versus about 40% below for IgG and IgA, then rebounded by 24 months. IgA remained stable; IgG, with the greatest clonal involvement, showed mixed changes with a rough 25% decline. The M+ subgroup was small (n=7), and few returned to range; return to reference range may therefore underestimate recovery despite substantial post-treatment rebound.

Among evaluable M+ patients, 63% in the BTKi cohort and all Ven patients achieved ≥50% suppression of involved FLC. Involved FLC remained suppressed as IgA rose during BTKi therapy and IgM rebounded after Ven, supporting concurrent clone reduction and immune reconstitution.

 Discussion: In BTKi, M+ patients had greater baseline humoral suppression, yet uninvolved IgA and IgG were preserved. Treatment produced concurrent clone reduction and humoral reconstitution, shown by declining tumor-derived Ig, sustained FLC suppression, and uninvolved Ig recovery. Isotype recovery differed:  IgA provided the clearest BTKi recovery signal when IgM was clonal; with fixed-duration Ven, IgM showed a marked treatment-related decline followed by post-treatment rebound, IgA remained stable and IgG showed minor, mixed changes. Thus, recovery appeared gradually during BTKi therapy and after Ven completion, supporting isotype- and regimen-specific interpretation. Paraproteinemia seen in CLL can confound assessment of Ig recovery and humoral immune status. The small Ven M+ cohort limited subgroup comparisons. Because the BTKi cohort was enriched for higher-risk disease by trial design, the relationship between paraproteinemia and baseline hypogammaglobulinemia warrants further study.

Farzeen Syed, DO: No relevant conflicts of interest to declare.